Abstract | BACKGROUND: METHOD: RESULTS: Evidence is presented for the ability of neuroleptics to chelate iron, mobilize it from peripheral stores, and deposit it in the basal ganglia. The effect of iron on dopaminergic receptor activity in brain and the potential role of iron in degenerative and neuroleptic-induced movement disorders are reviewed. The preponderance of the evidence shows a relationship between iron excess in the basal ganglia and the movement disorders. We found no studies that have examined the regulation of central levels of iron in patients with akathisia. CONCLUSION: The rationale for iron supplementation in the treatment of akathisia is relatively weak, and there are potentially adverse long-term consequences as outlined in our review. More research is required to directly measure the level of iron in the brain of patients with akathisia, e.g., using magnetic resonance imaging, before such therapeutic intervention can be recommended.
|
Authors | R Gold, R H Lenox |
Journal | The Journal of clinical psychiatry
(J Clin Psychiatry)
Vol. 56
Issue 10
Pg. 476-83
(Oct 1995)
ISSN: 0160-6689 [Print] United States |
PMID | 7559375
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antipsychotic Agents
- Receptors, Dopamine
- Iron
|
Topics |
- Akathisia, Drug-Induced
(drug therapy, etiology, physiopathology)
- Antipsychotic Agents
(adverse effects)
- Basal Ganglia
(metabolism)
- Brain
(metabolism)
- Dyskinesia, Drug-Induced
(etiology, metabolism)
- Humans
- Iron
(metabolism, physiology, therapeutic use)
- Iron Deficiencies
- Movement Disorders
(etiology, metabolism)
- Parkinson Disease
(etiology, metabolism)
- Receptors, Dopamine
(metabolism)
|